Pyxis Oncology (PYXS) Common Equity (2020 - 2026)

Pyxis Oncology (PYXS) has reported Common Equity for 7 consecutive years, with $11.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 86.95% year-over-year to $11.4 million in Q2 2026; TTM through Jun 2026 was $11.4 million, a 86.95% decrease from a year earlier, with the FY2025 full-year figure at $53.4 million, down 55.77% from the prior year.
• Common Equity was $11.4 million for Q2 2026 at Pyxis Oncology, down from $53.4 million in the prior quarter.
• Over five years, Common Equity peaked at $233.5 million in Q1 2022 and troughed at $11.4 million in Q2 2026.
• A 5-year average of $135.8 million and a median of $145.3 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 566.87% in 2022 and tumbled 86.95% in 2026, its largest moves.
• Over 5 years, Common Equity stood at $160.8 million in 2022, then fell by 21.84% to $125.7 million in 2023, then decreased by 3.94% to $120.8 million in 2024, then plunged by 55.77% to $53.4 million in 2025, then sank by 78.58% to $11.4 million in 2026.
• The last three Common Equity figures came in at $11.4 million (Q2 2026), $53.4 million (Q4 2025), and $68.8 million (Q3 2025), per Business Quant data.